CalciMedica, Inc. (NASDAQ:CALC) Insider Eric W. Roberts Purchases 5,000 Shares

CalciMedica, Inc. (NASDAQ:CALC) insider Eric W. Roberts acquired 5,000 shares of the stock in a transaction dated Thursday, June 27th. The stock was bought at an average cost of $3.22 per share, with a total value of $16,100.00. Following the completion of the purchase, the insider now owns 10,223 shares of the company’s stock, valued at $32,918.06. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

CalciMedica Stock Performance

NASDAQ CALC traded up $0.81 on Friday, hitting $3.96. 244,715 shares of the stock traded hands, compared to its average volume of 29,052. The business’s fifty day moving average is $5.27 and its two-hundred day moving average is $4.60. CalciMedica, Inc. has a 12 month low of $1.75 and a 12 month high of $8.38. The firm has a market capitalization of $42.57 million, a price-to-earnings ratio of -1.81 and a beta of 1.35.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.07. Analysts expect that CalciMedica, Inc. will post -2.05 EPS for the current fiscal year.

Hedge Funds Weigh In On CalciMedica

Institutional investors and hedge funds have recently bought and sold shares of the company. Hudson Bay Capital Management LP bought a new position in CalciMedica during the third quarter valued at $432,000. Meritage Portfolio Management boosted its holdings in shares of CalciMedica by 360.0% in the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after acquiring an additional 36,000 shares during the period. Finally, BML Capital Management LLC boosted its holdings in shares of CalciMedica by 63.8% in the fourth quarter. BML Capital Management LLC now owns 145,424 shares of the company’s stock worth $416,000 after acquiring an additional 56,643 shares during the period.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 target price on shares of CalciMedica in a report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of CalciMedica in a report on Thursday.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.